logo immunobrain
  • About us
    • Overview
    • Our History
    • Leadership
    • Partnerships
  • Our Science
    • Overview
    • Publications
    • Patents
  • Lead Program
    • IBC-Ab002 Antibody
    • IBC-01-01 Clinical Trial
  • Pipeline
  • News
  • Contact Us
Menu
  • About us
    • Overview
    • Our History
    • Leadership
    • Partnerships
  • Our Science
    • Overview
    • Publications
    • Patents
  • Lead Program
    • IBC-Ab002 Antibody
    • IBC-01-01 Clinical Trial
  • Pipeline
  • News
  • Contact Us

Publication Category: Our therapeutic approach

Harnessing Peripheral Immunity in Early Alzheimer’s Disease: Safety and Tolerability of IBC-Ab002 in an ongoing Phase 1b Clinical Trial

PD-L1 blockade therapeutic effect in Tau P301S (line PS19) mouse model of tauopathy

IBC-Ab002 Fc modifications for fast clearance are associated with advantageous safety profile

Alzheimer’s disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis

Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy

IBC-Ab002, an anti-PD-L1 monoclonal antibody tailored for treating Alzheimer’s disease

PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model

PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease

Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer’s disease pathology.

Aging-induced type I interferon response at the choroid plexus negatively affects brain function.

About Us
  • Overview
  • Our History
  • Leadership
  • Partnerships
Our Science
  • Overview
  • Patents
  • Publications
Lead Program
  • IBC-Ab002 Antibody
  • IBC-01-01 Clinical Trial
Pipeline
News
Contact Us
Follow us
  • Terms of Use
  • Privacy Statement
  • FCOI
  • Cookies Statement
  • Terms of Use
  • Privacy Statement
  • FCOI
  • Cookies Statement
Copyright © 2023 Immunobrain. All Rights Reserved.
Design PortnovMishan
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}